Wire · opportunities
Amgen's DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
Amgen's Imdelltra, a DLL3-targeted T-cell engager, demonstrated a statistically significant overall survival improvement as a first-line maintenance treatment for extensive stage small cell lung cancer when combined with AstraZeneca’s Imfinzi, potentially shifting the treatment paradigm earlier in the disease course.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must adjust your clinical and commercial strategy as Imdelltra moves earlier in lung cancer care, opening new competitive and partnership opportunities while requiring faster regulatory engagement.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics